Terran Biosciences Announces Development of Orally Active DMT, 5-MeO DMT, and Long-Lasting MDMA Prodrugs
Matthew King
$200M+ Invested in Bugatti Rimac, Liquid Death, Terran Biosciences, MoonPay and Others
We are excited to share that Valhalla Ventures portfolio company Terran Biosciences has created the first orally active prodrugs of DMT and 5-MeO-DMT in addition to novel, long-acting forms of MDMA.
Terran’s medicinal chemistry team advanced the prodrugs into animal PK studies and found multiple orally active forms of DMT and 5-MeO-DMT detailed in their recently published PCT patent application.
We believe this demonstrates the first time DMT has been made orally active without the use of a monoamine oxidase (MAO) inhibitor. An orally active form of DMT or 5-MeO-DMT may provide the best and easiest use profile for patients rather than other more complex methods such as injectable, inhaled, buccal, or sublingual methods of administration.
Additionally, Terran’s medicinal chemistry team has also produced a breakthrough in the MDMA space, with what we believe represents the world’s first long-acting prodrugs of MDMA demonstrated in animal pk models.
This improvement may eliminate the need for a booster dose during an MDMA therapy session, allowing a therapist to conduct the entire session without interruption.??
In spring of 2022 Valhalla reinvested in Terran’s Series B financing (our largest investment to date), and over the past year we have been repeatedly impressed by the progress made by the team.
Terran Biosciences is a unique player in the very noisy and crowded psychedelic therapeutics space, and is refreshingly differentiated in multiple facets including being the first ever psychedelics company to partner with a top-10 big pharma via their exclusive licensing deal with Sanofi.
We look forward to sharing a number of other breakthroughs in the coming months, as the Terran team has been working tirelessly toward their mission to deliver the benefits of psychedelic medicines to the largest possible population of patients in need.
For the original press release of the announcement, please click this link.
Contract Manufacturing for Therapeutic Development, AI & ML enthusiast, native California gardener
1 年Jennifer DePolo and I were just talking at our leadership meeting this week about the hurdles our clients encounter when manufacturing schedule 1 and 2 drugs. If your firm is looking for support in this, we can help.
Semi Retired and now giving back to the community
2 年Updated research on prescribing MAOIs https://www.cambridge.org/core/journals/cns-spectrums/article/prescribers-guide-to-classic-mao-inhibitors-phenelzine-tranylcypromine-isocarboxazid-for-treatmentresistant-depression/29C70FD3DA65E23A024D5E05C4369983
I'm passionate about helping people enhance their well-being through functional movement, yoga, breathwork, nature immersion, healing touch, and transformative retreats.
2 年I love how this field of psychedelic therapy is growing and evolving! Such potent and important medicine that will help the human race connect deeply with the heart and be able to create a better world from this place of understanding.
Building at the Intersection of Spatial Computing, Web3 & Blockchain
2 年Big!